<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02644486</url>
  </required_header>
  <id_info>
    <org_study_id>NJCT-1406</org_study_id>
    <nct_id>NCT02644486</nct_id>
  </id_info>
  <brief_title>A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhi-Hong Liu, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing University School of Medicine</source>
  <brief_summary>
    <textblock>
      To observe the decreased levels of low-density lipoprotein from baseline in patients with
      obesity-related glomerulopathy (ORG) after 12 weeks of Sevelamer Carbonate treatment.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    difficulty in enrollment
  </why_stopped>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>low-density lipoprotein</measure>
    <time_frame>12 weeks</time_frame>
    <description>decreased levels of low-density lipoprotein from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>uric acid</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes of uric acid from baseline after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood lipids parameters (CHO, TG, HDL)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes of blood lipids parameters from baseline after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proteinuria</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes of proteinuria from baseline after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood glucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes of blood glucose from baseline after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycated hemoglobin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes of glycated hemoglobin from baseline after 12 weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Obesity and Glomerulopathy</condition>
  <arm_group>
    <arm_group_label>A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dosage Sevelamer Carbonate + Irbesartan</intervention_name>
    <description>Sevelamer Carbonate 4.8g/d+Irbesartan 300mg/d</description>
    <arm_group_label>A Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dosage Sevelamer Carbonate + Irbesartan</intervention_name>
    <description>Sevelamer Carbonate 2.4g/d+Irbesartan 300mg/d</description>
    <arm_group_label>B Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan</intervention_name>
    <description>Irbesartan 300mg/d</description>
    <arm_group_label>C Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of obesity

          -  diagnosed ORG by renal biopsy

          -  LDL&gt;3.37mmol/L

          -  Proteinuria 0.5-3.5g/d

          -  eGFR (CKD-EPI formula) &gt; 30ml/min

        Exclusion Criteria:

          -  Other concomitant renal diseases

          -  Endocrine or drug-induced obesity;

          -  Type 2 diabetes

          -  eyes or obvious microscopic hematuria;

          -  Swallowing difficulty / severe gastrointestinal dysfunction

          -  intestinal obstruction;

          -  severe arrhythmia;

          -  Hypophosphatemia (&lt;0.7mmol/L);

          -  allergic to Sevelamer Carbonate

          -  unable to well cooperate

          -  Females who are in the period of gestation or lactation, or refuse to use
             contraception;

          -  participated in other clinical trial of drug within three months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>December 30, 2015</study_first_submitted>
  <study_first_submitted_qc>December 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <last_update_submitted>September 29, 2018</last_update_submitted>
  <last_update_submitted_qc>September 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing University School of Medicine</investigator_affiliation>
    <investigator_full_name>Zhi-Hong Liu, M.D.</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

